Readmission Rates and Medication Selection for Patients with Heart Failure Preserved Ejection Fraction

Troy Kramer PharmD^a
Carrie Vogler PharmD, BCPS^a
Robert Robinson, MD, MS, FACP^b
Mukul Bhattarai, MD, FACP^{b,c}

- a. Department of Pharmacy Practice, Southern Illinois University Edwardsville School of Pharmacy, Edwardsville, IL USA
- b. Division of General Internal Medicine, Department of Internal Medicine, Southern Illinois University Medicine, Springfield, IL USA
- c. Division of Cardiology, Southern Illinois University Medicine, Springfield, IL USA

Corresponding author:

Carrie Vogler Pharm.D, BCPS

Clinical Associate Professor

Department of Pharmacy Practice

Southern Illinois University Edwardsville School of Pharmacy, Edwardsville, IL USA

200 University Park Drive Edwardsville, IL 62026

Email: cvogler@siue.edu

Phone: 217-545-5394

Keywords: heart failure preserved ejection fraction, readmission, medications, HOSPITAL,

LACE index

Abstract

Purpose

Heart failure with preserved ejection fraction (HFpEF) has less guideline driven treatment options due to a lack of trials demonstrating medications with improved clinical outcomes for this patient population. The primary objective of this study is to determine which medications and dosages are related to high readmission rates for HFpEF patients.

Methods

A retrospective, single center, chart review was performed on patients with HFpEF at an academic medical center. Heart failure patients ages between 18-89 with an ejection fraction ≥45% from a transthoracic echocardiogram (TTE) were included. Primary outcomes include 30-day all cause readmission rates, prescribing patterns, and avoidance of potentially harmful medications. Descriptive statistics and multivariate logistic regression were used to assess potential risk factors.

Results

This study analyzed 455 patient admissions. Univariate analysis shows patients who were not readmitted were more likely to be on furosemide (54% vs 42%; p = 0.019). Conversely, readmitted patients were more likely to be taking bumetanide (4% vs 1%; p = 0.039). Lisinopril was the only angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) associated with lower readmission rates (p = 0.036). Multivariate logistic regression showed bumetanide on admission (OR 14.6, p = 0.001), discharged on rosuvastatin (OR 6.29, p = 0.003) and meloxicam therapy (OR 6.33, p = 0.003) to be independent predictors of hospital readmission.

Conclusion

Three independent pharmacologic predictors for 30-day readmissions for patients with HFpEF were therapy with bumetanide, meloxicam, or rosuvastatin. Further research is needed to clarify the significance of these results.

Introduction:

Background

Heart failure is a major public health concern in developed nations. In the United States, it is estimated that 5.7 million adults are living with some form of heart failure with an estimated total cost of 30.7 billion each year. 1,2 There are two major categories of heart failure; heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). While both conditions include significant patient morbidity and mortality, treatment options are not as well defined for HFpEF. HFpEF is commonly referred to as diastolic heart failure and includes patients with heart failure symptoms with an ejection fraction $\geq 45\%$, though the exact ejection fraction percentage has been debated. HFpEF accounts for nearly 50% of heart failure patients.³ There are a limited number of trials that show medications with clinical improvement for HFpEF patients and few treatments recommended in current practice guidelines. 4,5,6 Currently, the 2017 update to the AACF/AHA clinical practice guidelines recommends controlling blood pressure; however, it only gives moderate recommendations regarding agent selection with limited supporting data. The guidelines also recommend using diuretics for symptom control in volume overloaded patients. Further research is warranted to identify which medications result in the best clinical outcomes for patients and fewest number of hospitalizations.

HFpEF is a commonly encountered condition in the hospital setting, but the benefit of the medications prescribed and their impact on preventing hospital readmissions is not well studied. We studied the prescribing patterns of for HFpEF at Memorial Medical Center, a teaching hospital in Springfield, Illinois. An increase in knowledge regarding patient outcomes for various

drug regimens will help to improve medication selection and reduce complications for future patients.

Methods:

Study Design

This study was a single centered retrospective review of medications prescribed to patients with HFpEF. The study protocol was approved by the institutional review board prior to beginning the study. Patients reviewed included admission or discharge diagnosis ICD-9 or ICD-10 codes for diastolic heart failure (HFpEF) between 12/6/2016 and 12/6/2018. Data collection included recording admission and discharge medications that relate to heart failure for each patient. A comprehensive list of medications recorded can be seen in Tables 2-4. Medications that are commonly used for HFrEF were investigated for their potential use in patients with HFpEF. These medications were sourced from AACF/AHA 2017 clinical practice guidelines⁶. The chosen medications to avoid in heart failure examined in this trial are a subset of the 2016 AHA list of medications that may cause or exacerbate heart failure.

Patient Population

Eligible patients were between the ages of 18-89 with an admission to the internal medicine hospitalist service, and an ejection fraction of \geq 45% reported on a TTE during admission or within previous 6 months. Patients who were on hospice, died during their hospital stay, had a past medical history of valvular heart disease, a history of cardiotoxicity due to chemotherapy, or receiving chemotherapy were excluded from the study.

Outcomes

The primary efficacy outcomes were 30-day all cause readmission rates for patients with HFpEF.

Other primary outcomes include selection of medications for HFpEF and avoidance of

medications that should be avoided in heart failure patients. Secondary outcomes include patient safety measured by evaluating readmission rates between patients.

Statistical analysis

A HOSPITAL score, LACE index, Charlson Comorbidity Score were calculated and compared for each admission. Qualitative variables were compared using Pearson chi² or Fisher's exact test and reported as frequency (%). Quantitative variables were compared using the non-parametric Mann–Whitney U test and reported as mean \pm standard deviation. Variables from univariate analysis with a p value of 0.05 or less were evaluated using multivariate logistic regression with backwards likelihood ration based selection. Statistical analyses were performed using SPSS version 22 (SPSS Inc., Chicago, IL, USA). Two sided P-values < 0.05 were considered significant.

Results:

Population Baseline

A total of 455 unique admissions were analyzed. Results for all cause readmissions within 30-days are listed in Tables 1-4. Baseline characteristics between those who were not readmitted within 30-days versus those who were readmitted within 30-days are summarized in Table 1. The two groups were comparable in their medical comorbidities as indicated by their Charlson Comorbidity index. Those who were readmitted within 30-days were more likely to have had hospital readmissions within the past year (p = 0.008). These patients were also more likely to have a higher HOSPITAL score (p < 0.001) with an odds ratio of 1.23 (1.05-1.44, 95% CI). The HOSPITAL score is a validated screening tool used to help identify potentially avoidable 30-day readmissions using seven defined attributes at patient discharge.

Medications on Admission

Four admission medications were found to be statistically significant in relation to 30-days all cause readmissions as summarized in Table 2. Lisinopril was the only angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) associated with a lower rate of readmissions (p = 0.036). Two of the three medications in the loop diuretic class were found to have significant correlations with readmissions. The three loop diuretics that were investigated were furosemide, torsemide, and bumetanide. Patients coming to the hospital on furosemide were associated with a lower 30-day readmission (p = 0.001). Conversely, patients who were on bumetanide were associated with higher rates of 30-day readmissions (p < 0.001) with an odds ratio of 14.6 (3.12-68.67, 95% CI). There was no statistical difference for patients who were on torsemide. The final drug that was found to be statistically significant in correlation to 30-day all cause readmissions was rosuvastatin. Patients who were on rosuvastatin on admission were associated with a greater occurrence of 30-day readmissions (p = 0.011).

Medications on Discharge

Discharge medications for patients with HFpEF and how they relate to 30-day all cause readmission rates is summarized in Table 3. Enalapril was associated with increased readmissions (p = 0.032) and was the only ACE inhibitor or ARB to show a statistically significant increase in readmissions for discharge medications. There were two loop diuretics that showed statistical significance with discharge medications for 30-day readmissions. Patients who were readmitted within 30-days were more likely to be taking bumetanide from their last discharge (p = 0.039) while patients readmitted within 30-days were less likely to be taking furosemide from their last discharge (p = 0.019). For other medications, rosuvastatin was the only other medication found to be statistically significant since patients readmitted within 30-

days were more likely to be taking rosuvastatin than those who were not (p = 0.002) with an odds ratio of 6.29 (1.83-21.60, 95% CI).

Medications to Avoid in Heart Failure

Readmission rates for patients taking medications that should be avoided in heart failure are summarized in Table 4. Meloxicam was the only medication found to be associated with 30-day all cause readmissions for HFpEF patients (p = 0.002) with an odds ratio of 6.33 (1.87-21.43, 95% CI). Meloxicam may have this effect with its inhibition of prostaglandin synthesis promoting water retention.

Multivariate analysis

Multivariate logistic regression showed burnetanide on admission (OR 14.6, p = 0.001), being discharged on rosuvastatin (OR 6.29, p = 0.003), meloxicam therapy (OR 6.33, p = 0.003), an elevated HOSPITAL score (OR 1.23, p = 0.011) and an elevated platelet count (OR 1.00, p = 0.011) to be independent predictors of hospital readmission.

Discussion:

Overall, lisinopril, enalapril, furosemide, bumetanide, rosuvastatin, and meloxicam had a statistically significant correlation with readmission rates for HFpEF patients. The difference in the loop diuretics appears to be the most clinically relevant finding. Furosemide was found to correlate with less 30-day readmission rates while bumetanide was found to correlate with more 30-day readmissions. A follow up comparing equivalent dosing between these two agents may be warranted. These findings with furosemide agree with the ACC/AHA/HFSA 2017 practice guidelines of using diuretics to symptomatic volume control for furosemide, but disagree with bumetanide because despite being an agent used for volume control, it was associated with higher readmissions.⁶

Rosuvastatin was the only member in its class to show significance in 30-day readmissions. While all statins were reviewed, one possible explanation is that the intensity of the statin could have an effect on patient outcomes. Rosuvastatin and atorvastatin both are indicated for both high intensity and moderate intensity statin therapy. Since atorvastatin did not show statistical significance in all cause 30-day readmissions, statin intensity may not be the reason for this result unless patients on rosuvastatin were more likely to be on a different intensity therapy than those taking atorvastatin. Analyzing readmission rates in relation to statin intensity would provide further insight into this.

Other drugs commonly used in patients with HFrEF including ACE inhibitors, ARBs, and beta blockers did not show any statistically significant correlation with 30-day readmissions. One previous study had shown the potential for candesartan to have a moderate impact in reducing hospitalizations in patients with HFpEF. While this study did not look directly at candesartan, there were two other ARBs examined. This study did not find any statistically significant correlation between patients on ARBs and 30-day readmissions.

For the use of aldosterone antagonists in HFpEF, it was found that there was no statistically significant correlation between their use and 30-day all cause readmissions. These results are consistent with the TOPCAT trial evaluating the use of spironolactone for HFpEF patients. In this prospective double-blind placebo-controlled trial, it was found that spironolactone did not significantly impact all cause hospitalization rates (18.8 hospitalizations per 100 person-years in the spironolactone group and 20.0 per 100 person-years in the placebo group, (hazard ratio 0.94 (0.85-1.04, 95% CI, p=0.25))¹⁰. The TOPCAT trial did, however, show significance for reducing hospitalizations for heart failure, (3.8 hospitalizations for heart failure per 100 person-years in the spironolactone group vs. 4.6 per 100 person-years in the placebo

group; hazard ratio 0.83 (0.69 to 0.99, 95% CI, p=0.04)), which may mark an area for further

study¹⁰.

One of the limitations to this study is the sample size. Many of the drugs analyzed had a

relatively small number of patients taking them which increases the likelihood of a type 2 error.

Another limitation involves safety outcomes with nonsteroidal anti-inflammatory drugs

(NSAIDs). It is possible that patients may take over the counter NSAIDs without reporting them

in their medication list which makes them difficult to track. Patients using these medications to

help with pain relief may take them as needed which makes them difficult to assess for use.

Medications adherence and side effects were not assessed in this study which could impact the

readmission rates if patients were not talking their diuretics as prescribed. Strengths of the study

are that it was a single centered and had one hospitalist group which reduces variability in

documentation and charting of patient data.

Conclusion:

In the study there were four identified potential risk factors for 30-day readmissions for patients

with HFpEF as shown in Table 5. These were found to be HOSPITAL score, patients on

bumetanide on admission, discharge on rosuvastatin, and patients on meloxicam on admission..

In treatment of patients with HFpEF, furosemide appeared to be associated with the lowest

frequency of readmissions. This suggests that prescribing patterns of specific loop diuretics and

may make a significant impact in preventing patients from becoming readmitted.

Acknowledgements: Nicolas Ferry, SIU Medical Student for his assistance in data collection.

Author contributions: All authors contributed to this work.

Conflict of Interest: The authors have no conflicts of interest to disclose.

Funding: No funding was obtained for this study.

References:

- 1. Mozzafarian D, Benjamin EJ, Go AS, et al., Heart disease and stroke statistics—2016 update: a report from the American Heart Association. *Circulation*. 2016;133:e38-e360.
- 2. Heidenreich PA, Trogdon JG, Khavjou OA et al., Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association.

 *Circulation. 2011;123(8):933–44.
- 3. Dunlay SM, Roger VL, Redfield MM. Epidemiology of Heart Failure with Preserved Ejection Fraction. *Nature Reviews Cardiology*. 2017; 14: 591–602.
- 4. Harper AR, Patel HC, Lyon AR. Heart Failure with Preserved Ejection Fraction. *Clin Med.* 2018; 18:24-29.
- 5. Domagoj M, Branka JZ, Jelena M, et al., Effects of Carvedilol Therapy in Patients with Heart Failure with Preserved Ejection Fraction Results from the Croation Heart Failue (CRO-HF) Registry. *Med Clin* (Barc). 2018.
- 6. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA.
- 7. Page RL, O'bryant CL, Cheng D, et al. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2016;
- 8. Donzé JD, Williams MV, Robinson EJ, Zimlichman E, Aujesky D, Vasilevskis EE, et al. International Validity of the HOSPITAL Score to Predict 30-Day Potentially Avoidable Hospital Readmissions. *JAMA Intern Med.* 2016 Apr;176(4):496–502.

- 9. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. *Lancet*. 2003;362(9386):777-81.
- 10. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. *N Engl J Med*. 2014;370(15):1383-92.

Table 1. Baseline characteristics of the study population by 30-day readmission status

	Not readmitted with		
	30-days n = 317	within 30-days n = 128	p value
Age, mean (SD)	69 (12)	67 (12)	0.250
Female (%)	184	86	0.230
Length of stay (SD)	6.2 (5.12)	6.16 (4.22)	0.938
Hospital admissions in the last year (SD)	0.24 (0.68)	0.58 (1.42)	0.008
Emergency department visits in last 6 months (SD)	0.13 (0.49)	0.14 (0.43)	0.805
Echocardiographic data			
LVEF (SD)	57% (9.7)	58% (9.9)	0.185
Pulmonary Artery Pressure	44 (17.7)	42 (15.2)	0.399
E/e' Ratio	16.33 (8.2)	15.14 (7.7)	0.223
	(.= /	. ()	
HOSPITAL Score (SD)	4.10 (1.38)	4.73 (1.60)	<0.001
LACE Index (SD)	10.61 (1.87)	10.80 (1.94)	0.338
Charlson Comorbidity Score (SD)	3.39 (1.18)	3.31 (1.10)	0.489
Medical Comorbidities (%)			
Myocardial infarction	71	23	0.165
Peripheral artery disease	30	8	0.194
Stroke	27	9	0.468
Dementia	10	3	0.564
Chronic lung disease	193	92	0.241
Connective tissue disease	14	5	0.697
Peptic ulcer disease	5	4	0.352
Cirrhosis	31	17	0.418
Diabetes without complications	130	51	0.417
Diabetes with complications	129	54	0.755
Paralysis	10	0	0.035
Renal disease	148	66	0.823
Cancer	20	13	0.240
Metastatic cancer	4	6	0.039
Admission laboratory values			
Hemoglobin units (SD)	10.92 (2.47)	10.57 (2.12)	0.136
Platelet (units) (SD)	231 (88.7)	251 (97.5)	0.036
White blood cell count (SD)	10.53 (5.30)	10.37 (5.01)	0.757
Blood urea nitrogen (SD)	29.21 (19.3)	30.30 (20.27)	0.590
Creatinine (SD)	1.76 (1.39)	2.11 (2.10)	0.079
Potassium (SD)	4.21 (0.68)	4.32 (0.760)	0.073
Sodium (SD)	136.43 (4.86)	135.80 (4.31)	0.172
Body mass index (SD)	37.42 (15.49)	35.72 (12.56)	0.172

Table 2. Admission Medic	auons by 30-day readm		Doodusitted		
		Not Readmitted readmitted within 30-da		ivs	
		within 30-days	ariamire days		
Medication Class	Medication	N = 317	N = 138	p value	
ACE Inhibitors	Benazepril	1 (1%)	1 (1%)	0.544	
	Enalapril	2 (1%)	0	0.350	
	Lisinopril	102 (32%)	31 (22%)	0.036	
	Quinapril	1 (1%)	0	0.509	
Angiotensin receptor blocker	Losartan	28 (9%)	11 (8%)	0.763	
	Valsartan	4 (1%)	1 (1%)	0.613	
Beta Blockers	Atenolol	6 (2%)	1 (1%)	0.352	
	Bisoprolol	8 (3%)	0	0.60	
	Carvedilol	63 (20%)	27 (20%)	0.939	
	Labetalol	1 (1%)	2 (1%)	0.170	
	Metoprolol Succinate	75 (24%)	28 (20%)	0.430	
	Metoprolol Tartrate	57 (18%)	19 (14%)	0.268	
Cardiac Glycosides	Digoxin	12 (4%)	6 (4%)	0.77	
Loop diuretics	Bumetanide	2 (1%)	12 (9%)	<0.001	
	Furosemide	172 (54%)	52 (38%)	0.001	
	Torsemide	26 (8%)	5 (4%)	0.075	
Nitrates	Isosorbide Dinitrate	3 (1%)	0	0.252	
	Isosorbide Mononitrate	34 (11%)	18 (13%)	0.475	
Statins	Atorvastatin	111 (35%)	46 (33%)	0.729	
	Lovastatin	12 (4%)	7 (5%)	0.528	
	Pitavastatin	1 (1%)	0	0.509	
	Pravastatin	32 (10%)	13 (9%)	0.825	
	Rosuvastatin	6 (2%)	9 (7%)	0.011	
	Simvastatin	19 (6%)	14 (10%)	0.117	
Other	HCTZ	19 (6%)	12 (9%)	0.293	
	Metolozone	9 (3%)	5 (4%)	0.656	
	Spironolactone	31 (10%)	12 (9%)	0.716	
	Triamterene	4 (1%)	4 (1%)	0.22	

Table 3. Discharge Medica	Table 5. Discharge Medications by Readmission Status				
		Not readmitted	Readmitted within 30-days		
		within 30-days	within 50-uays		
Medication Class	Medication	N = 317	N = 138	p value	
ACE Inhibitors	Benazepril	2 (1%)	0	0.350	
7.02 ////////////////////////////////////	Enalapril	0	2 (1%)	0.032	
	Lisinopril	85 (27%)	26 (19%)	0.069	
	Quinapril	0	0	0,000	
	Quinapini				
Angiotensin receptor blocker	Losartan	20 (6%)	7 (5%)	0.608	
	Valsartan	1 (1%)	1 (1%)	0.544	
		_ (= : -)	_ (=)		
Beta Blockers	Atenolol	4 (1%)	0	0.185	
	Bisoprolol	6 (2%)	1 (1%)	0.352	
	Carvedilol	83 (26%)	30 (22%)	0.313	
	Labetalol	1 (1%)	3 (2%)	0.051	
	Metoprolol Succinate	55 (17%)	29 (34%)	0.354	
	Metoprolol Tartrate	67 (21%)	23 (17%)	0.271	
Cardiac Glycosides	Digoxin	15 (5%)	6(4%)	0.858	
·		,	, ,		
Loop diuretics	Bumetanide	4 (1%)	6 (4%)	0.039	
	Furosemide	171 (54%)	58 (42%)	0.019	
	Torsemide	24 (8%)	5 (4%)	0.113	
Nitrates	Isosorbide Dinitrate	3 (1%)	0	0.252	
	Isosorbide Mononitrate	28 (9%)	17 (12%)	0.252	
Statins	Atorvastatin	126 (40%)	52 (37%)	0.678	
	Lovastatin	9 (3%)	5 (4%)	0.656	
	Pitavastatin	1 (1%)	0	0.509	
	Pravastatin	26 (8%)	13 (9%)	0.670	
	Rosuvastatin	4 (1%)	9 (7%)	0.002	
	Simvastatin	17 (5%)	12 (9%)	0.181	
Other Diuretics	HCTZ	13 (4%)	5 (4%)	0.810	
	Metolozone	6 (2%)	0	0.104	
	Spironolactone	29 (6%)	9 (7%)	0.829	
	Triamterene	3 (1%)	2 (1%)	0.636	

Table 4. Medications to be avoided with HFpEF by Readmission Status

	•	Not readmitted within 30-days	Readmitted within 30-days	
Medication Class	Medication	N = 317	N = 138	p value
Alpha blocker	Doxazosin	7 (2%)	0	0.079
Beta blocker	Sotalol	0	2 (1%)	0.032
Biguanide	Metformin	47 (15%)	15 (11%)	0.258
Calcium channel blocker	Diltiazem	16 (5%)	8 (6%)	0.742
	Nifedipine	31 (10%)	9 (7%)	0.259
	Verapamil	4 (1%)	3 (2%)	0.467
Gabapentinoid	Pregabalin	21 (7%)	12 (9%)	0.434
NSAID	Celecoxib	5 (2%)	1 (1%)	0.464
	Ibuprofen	15 (5%)	2 (1%)	0.090
	Meloxicam	4 (1%)	9 (7%)	0.002
	Naproxen	2 (1%)	2 (1%)	0.390
SSRI	Citalopram	22 (7%)	8 (6%)	0.652
TCA	Amitryptyline	16 (5%)	3 (2%)	0.159
	Nortryptyline	2 (1%)	2 (1%)	0.390

American Heart Association (2016). Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association

Table 5. Multivariate logistic regression of potential risk factors for hospital readmission within 30-days of discharge.

	Odds Ratio (95% CI)	P value
HOSPITAL score	1.23 (1.05 – 1.44)	0.011
Bumetanide on admission	14.6 (3.12 – 68.67)	0.001
Discharged on Rosuvastatin	6.29 (1.83 – 21.60)	0.003
Meloxicam therapy	6.33 (1.87 - 21.43)	0.003
Platelet count	1.00 (1.00 – 1.01)	0.011